U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H5F3N2OS
Molecular Weight 234.198
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RILUZOLE

SMILES

NC1=NC2=CC=C(OC(F)(F)F)C=C2S1

InChI

InChIKey=FTALBRSUTCGOEG-UHFFFAOYSA-N
InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)

HIDE SMILES / InChI

Molecular Formula C8H5F3N2OS
Molecular Weight 234.198
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/riluzole.html http://www.rxlist.com/rilutek-drug.htm https://www.ncbi.nlm.nih.gov/pubmed/8813989

Riluzole, a member of the benzothiazole class, is indicated for the treatment of patients with amyotrophic lateral sclerosis. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on glutamate release (activation of glutamate reuptake), 2) inactivation of voltage-dependent sodium channels, and 3) ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors. Common adverse reactions include headache, abdominal pain, back pain, vomiting, dyspepsia, diarrhea, dizziness. Riluzole-treated patients that take other hepatotoxic drugs may be at increased risk for hepatotoxicity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q12791|||Q5SQR9
Gene ID: 3778.0
Gene Symbol: KCNMA1
Target Organism: Homo sapiens (Human)
2.3 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RILUTEK

Approved Use

RILUTEK is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS). Riluzole extends survival and/or time to tracheostomy.

Launch Date

1995
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
359 ng/mL
50 mg 1 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RILUZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2257 ng × h/mL
50 mg 1 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RILUZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.8 h
50 mg 1 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RILUZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
RILUZOLE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1429
unhealthy, ADULT
n = 244
Health Status: unhealthy
Condition: amyotrophic lateral sclerosis
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 244
Sources: Page: p.1429
Disc. AE: Lung function decreased...
Other AEs: AST increased, Vomiting...
AEs leading to
discontinuation/dose reduction:
Lung function decreased (4%)
Other AEs:
AST increased (11.9%)
Vomiting (1%)
Abdominal pain (3%)
Dizziness (1%)
Asthenia (4%)
Malaise (2%)
Nausea (5%)
Sources: Page: p.1429
AEs

AEs

AESignificanceDosePopulation
Dizziness 1%
100 mg 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1429
unhealthy, ADULT
n = 244
Health Status: unhealthy
Condition: amyotrophic lateral sclerosis
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 244
Sources: Page: p.1429
Vomiting 1%
100 mg 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1429
unhealthy, ADULT
n = 244
Health Status: unhealthy
Condition: amyotrophic lateral sclerosis
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 244
Sources: Page: p.1429
AST increased 11.9%
100 mg 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1429
unhealthy, ADULT
n = 244
Health Status: unhealthy
Condition: amyotrophic lateral sclerosis
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 244
Sources: Page: p.1429
Malaise 2%
100 mg 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1429
unhealthy, ADULT
n = 244
Health Status: unhealthy
Condition: amyotrophic lateral sclerosis
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 244
Sources: Page: p.1429
Abdominal pain 3%
100 mg 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1429
unhealthy, ADULT
n = 244
Health Status: unhealthy
Condition: amyotrophic lateral sclerosis
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 244
Sources: Page: p.1429
Asthenia 4%
100 mg 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1429
unhealthy, ADULT
n = 244
Health Status: unhealthy
Condition: amyotrophic lateral sclerosis
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 244
Sources: Page: p.1429
Lung function decreased 4%
Disc. AE
100 mg 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1429
unhealthy, ADULT
n = 244
Health Status: unhealthy
Condition: amyotrophic lateral sclerosis
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 244
Sources: Page: p.1429
Nausea 5%
100 mg 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1429
unhealthy, ADULT
n = 244
Health Status: unhealthy
Condition: amyotrophic lateral sclerosis
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 244
Sources: Page: p.1429
OverviewDrug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
unlikely
unlikely
unlikely
unlikely
yes
yes
yes
likely (co-administration study)
Comment: Potential inhibitors of CYP1A2 (e.g. caffeine, phenacetin, theophylline, amitriphtyline, and quinolones) could decrease the rate of riluzole elimination, while inducers of CYP1A2 (e.g. cigarette smoke, charcoal-broiled food, rifampicin, and omeprazole) could increase rate of riluzole elimination
Page: 8.0
yes
no (pharmacogenomic study)
Tox targets
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review.
2001
[Symptomatic treatment and palliative care of ALS].
2001
Pharmacological treatment of ALS.
2001
Multiple system atrophy: pathophysiology and management.
2001
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
2001
Differential cortico-motoneuron vulnerability after chronic mitochondrial inhibition in vitro and the role of glutamate receptors.
2001 Dec 20
Characteristics of hippocampal glycine release in cell-damaging conditions in the adult and developing mouse.
2001 Jul
Riluzole-induced acute pancreatitis.
2001 Jul
[Amyotrophic lateral sclerosis].
2001 Jul 27
Effect of the neuroprotective agent riluzole on intracellular Ca2+ levels in IMR32 neuroblastoma cells.
2001 Jun
A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group.
2001 Mar
Examining the evidence about treatment in ALS/MND.
2001 Mar
Slowing down ALS--is this good or bad?
2001 Mar
Riluzole suppresses post-sigh, but not spontaneous apnoeas during sleep in rats.
2001 Nov
Neuroprotective effect of riluzole in MPTP-treated mice.
2001 Nov 9
Riluzole in Huntington's disease (HD): an open label study with one year follow up.
2001 Oct
Neuroprotective agent riluzole dramatically slows inactivation of Kv1.4 potassium channels by a voltage-dependent oxidative mechanism.
2001 Oct
Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS.
2001 Oct 15
The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK.
2001 Oct 15
Prognostic value of decremental responses to repetitive nerve stimulation in ALS patients.
2001 Sep 11
Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes.
2001 Sep 14
Riluzole for motor neurone disease. Reply from chairman of appraisal committee at NICE.
2001 Sep 8
Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity.
2002
A fair innings for NICE?
2002
Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.
2002
Workshop on primary progressive multiple sclerosis: meeting summary.
2002 Apr
Sodium channel-blocking agents are not of benefit to rats with kaolin-induced hydrocephalus.
2002 Aug
Molsidomine potentiates the protective activity of GYKI 52466, a non-NMDA antagonist, MK-801, a non-competitive NMDA antagonist, and riluzole against electroconvulsions in mice.
2002 Aug
Modulation of recombinant and native neuronal SK channels by the neuroprotective drug riluzole.
2002 Aug 2
An ACTH- and ATP-regulated background K+ channel in adrenocortical cells is TREK-1.
2002 Dec 20
Riluzole therapy in cervical dystonia.
2002 Jan
Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.
2002 Jan
Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
2002 Jul
Effect of chronic treatment with riluzole on the nigrostriatal dopaminergic system in weaver mutant mice.
2002 Jul
Effect of Riluzole on serum amino acids in patients with amyotrophic lateral sclerosis.
2002 Jul
Early symptom progression rate is related to ALS outcome: a prospective population-based study.
2002 Jul 9
How useful are retrospective studies in evaluating therapeutic interventions?
2002 Mar
A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease.
2002 Mar
Is glutamate involved in transient lower esophageal sphincter relaxations?
2002 Mar
Riluzole and olanzapine in Huntington's disease.
2002 Mar
Kainate-induced currents in rat cortical neurons in culture are modulated by riluzole.
2002 Mar 15
Interaction between vanilloid and glutamate receptors in the central modulation of nociception.
2002 Mar 29
A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis.
2002 May
Riluzole treatment in advanced ALS.
2002 May
Respiratory rhythm: an emergent network property?
2002 May 30
Voltage-gated sodium ion channels in prostate cancer: expression and activity.
2002 May-Jun
Effect of riluzole on cytosolic Ca2+ increase in human osteosarcoma cells.
2002 Nov
Interaction of high concentrations of riluzole with recombinant skeletal muscle sodium channels and adult-type nicotinic receptor channels.
2002 Oct
Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity.
2002 Sep 15
Adjunctive modafinil in ALS.
2002 Spring
Patents

Sample Use Guides

50 mg twice daily, taken at least 1 hour before or 2 hours after a meal
Route of Administration: Oral
In Vitro Use Guide
In vitro incubation of [14C]riluzole (15 microM) with human hepatic microsomes and NADPH or UDPGA cofactors resulted in formation of N-hydroxyriluzole (K(m) = 30 microM) or an unidentified glucuroconjugate (K(m) = 118 microM). Human microsomal riluzole N-hydroxylation was most strongly inhibited by the CYP1A2 inhibitor alpha-naphthoflavone (IC50 = 0.42 microM). Thus, riluzole is predominantly metabolized by CYP1A2 in human hepatic microsomes to N-hydroxyriluzole.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:56:10 GMT 2023
Edited
by admin
on Fri Dec 15 15:56:10 GMT 2023
Record UNII
7LJ087RS6F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RILUZOLE
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
RILUZOLE [USP-RS]
Common Name English
RILUZOLE [ORANGE BOOK]
Common Name English
Riluzole [WHO-DD]
Common Name English
riluzole [INN]
Common Name English
RP 54274
Code English
NSC-753433
Code English
RILUZOLE [EMA EPAR]
Common Name English
RILUZOLE [USP IMPURITY]
Common Name English
EXSERVAN
Brand Name English
2-BENZOTHIAZOLAMINE, 6-(TRIFLUOROMETHOXY)-
Systematic Name English
RP-54274
Code English
TIGLUTIK
Brand Name English
RILUZOLE [USAN]
Common Name English
RILUZOLE [MI]
Common Name English
RILUZOLE [MART.]
Common Name English
NSC-759823
Code English
RILUZOLE [JAN]
Common Name English
2-Amino-6-(trifluoromethoxy)benzothiazole
Systematic Name English
RILUZOLE [USP MONOGRAPH]
Common Name English
RILUTEK
Brand Name English
BHV-0223
Code English
Classification Tree Code System Code
WHO-ATC N07XX02
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
FDA ORPHAN DRUG 508715
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
LIVERTOX NBK548919
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
NDF-RT N0000167094
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
FDA ORPHAN DRUG 509415
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
NDF-RT N0000167094
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
FDA ORPHAN DRUG 510015
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
FDA ORPHAN DRUG 563216
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
NDF-RT N0000167094
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
EMA ASSESSMENT REPORTS RILUZOLE ZENTIVA (AUTHORIZED: AMYOTROPHIC LATERAL SCLEROSIS)
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
FDA ORPHAN DRUG 72792
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
NDF-RT N0000167094
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
NDF-RT N0000175740
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
FDA ORPHAN DRUG 100796
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
WHO-VATC QN07XX02
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
EMA ASSESSMENT REPORTS RILUTEK (AUTHORIZED: AMYOTROPHIC LATERAL SCLEROSIS)
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
EU-Orphan Drug EU/3/14/1401
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
NCI_THESAURUS C264
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
Code System Code Type Description
IUPHAR
2326
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
USAN
GG-81
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
MESH
D019782
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
DAILYMED
7LJ087RS6F
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
CAS
1744-22-5
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
LACTMED
Riluzole
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
DRUG BANK
DB00740
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
FDA UNII
7LJ087RS6F
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
PUBCHEM
5070
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
RXCUI
35623
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY RxNorm
INN
5912
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
EVMPD
SUB10319MIG
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
WIKIPEDIA
RILUZOLE
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
NSC
753433
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
RS_ITEM_NUM
1604337
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
DRUG CENTRAL
2382
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
EPA CompTox
DTXSID3045192
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
NSC
759823
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
MERCK INDEX
m9620
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL744
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
NCI_THESAURUS
C47704
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
SMS_ID
100000089184
Created by admin on Fri Dec 15 15:56:10 GMT 2023 , Edited by admin on Fri Dec 15 15:56:10 GMT 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
Inhibits TDP-43 hyperphosphorylation
IC50
TARGET -> INHIBITOR
INHIBITS GLUTAMATE RELEASE
Related Record Type Details
METABOLITE -> PARENT
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC DOSE
PHARMACOKINETIC
Route of adminIstration
PHARMACOKINETIC
Cmax PHARMACOKINETIC ROUTE OF ADMINISTRATION
PHARMACOKINETIC